KR20180102215A - 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도 - Google Patents

관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도 Download PDF

Info

Publication number
KR20180102215A
KR20180102215A KR1020187025773A KR20187025773A KR20180102215A KR 20180102215 A KR20180102215 A KR 20180102215A KR 1020187025773 A KR1020187025773 A KR 1020187025773A KR 20187025773 A KR20187025773 A KR 20187025773A KR 20180102215 A KR20180102215 A KR 20180102215A
Authority
KR
South Korea
Prior art keywords
antibody
eta
seq
glu
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187025773A
Other languages
English (en)
Korean (ko)
Inventor
안토니 마로타
Original Assignee
더 유니버시티 오브 브리티쉬 콜롬비아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 브리티쉬 콜롬비아 filed Critical 더 유니버시티 오브 브리티쉬 콜롬비아
Publication of KR20180102215A publication Critical patent/KR20180102215A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001163—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
KR1020187025773A 2007-11-27 2008-11-26 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도 Ceased KR20180102215A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99052007P 2007-11-27 2007-11-27
US60/990,520 2007-11-27
US7712308P 2008-06-30 2008-06-30
US61/077,123 2008-06-30
PCT/CA2008/002094 WO2009067811A1 (en) 2007-11-27 2008-11-26 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167029986A Division KR101945394B1 (ko) 2007-11-27 2008-11-26 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20180102215A true KR20180102215A (ko) 2018-09-14

Family

ID=40677991

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020187025773A Ceased KR20180102215A (ko) 2007-11-27 2008-11-26 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
KR1020167029986A Active KR101945394B1 (ko) 2007-11-27 2008-11-26 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
KR1020177027282A Ceased KR20170116184A (ko) 2007-11-27 2008-11-26 관절염의 예방과 치료를 위한 14-3-3 길항제
KR1020107014289A Ceased KR20100100912A (ko) 2007-11-27 2008-11-26 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
KR1020107014288A Ceased KR20100099221A (ko) 2007-11-27 2008-11-26 관절염의 예방과 치료를 위한 14-3-3 길항제

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020167029986A Active KR101945394B1 (ko) 2007-11-27 2008-11-26 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
KR1020177027282A Ceased KR20170116184A (ko) 2007-11-27 2008-11-26 관절염의 예방과 치료를 위한 14-3-3 길항제
KR1020107014289A Ceased KR20100100912A (ko) 2007-11-27 2008-11-26 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
KR1020107014288A Ceased KR20100099221A (ko) 2007-11-27 2008-11-26 관절염의 예방과 치료를 위한 14-3-3 길항제

Country Status (12)

Country Link
US (6) US20110027269A1 (cg-RX-API-DMAC10.html)
EP (4) EP3192808A1 (cg-RX-API-DMAC10.html)
JP (5) JP5781764B2 (cg-RX-API-DMAC10.html)
KR (5) KR20180102215A (cg-RX-API-DMAC10.html)
CN (3) CN101952313B (cg-RX-API-DMAC10.html)
AU (2) AU2008329466B2 (cg-RX-API-DMAC10.html)
BR (2) BRPI0819063A2 (cg-RX-API-DMAC10.html)
CA (2) CA2706476C (cg-RX-API-DMAC10.html)
HK (1) HK1253516A1 (cg-RX-API-DMAC10.html)
IL (3) IL205907A0 (cg-RX-API-DMAC10.html)
PL (1) PL3192807T3 (cg-RX-API-DMAC10.html)
WO (2) WO2009067811A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2021792T3 (pl) 2006-05-09 2013-08-30 Univ British Columbia Rozpuszczone białkowe markery zapalenia stawów
BRPI0819063A2 (pt) 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
PT2406633T (pt) * 2009-03-11 2019-03-14 Augurex Life Sciences Corp Composições e métodos para caracterizar condições artríticas
US9474540B2 (en) 2009-10-08 2016-10-25 Ethicon-Endo-Surgery, Inc. Laparoscopic device with compound angulation
US8562592B2 (en) 2010-05-07 2013-10-22 Ethicon Endo-Surgery, Inc. Compound angle laparoscopic methods and devices
US9226760B2 (en) 2010-05-07 2016-01-05 Ethicon Endo-Surgery, Inc. Laparoscopic devices with flexible actuation mechanisms
GB201016494D0 (en) 2010-09-30 2010-11-17 Queen Mary Innovation Ltd Polypeptide
CN104011068A (zh) 2011-10-21 2014-08-27 奥古雷克斯生命科学公司 衍生自瓜氨酸化的14-3-3的抗原及其在风湿性关节炎诊断中的用途
GB201200555D0 (en) * 2012-01-13 2012-02-29 Univ Birmingham Peptide
CN103060360A (zh) * 2013-01-04 2013-04-24 昆明理工大学 黑大豆14-3-3j蛋白基因的原核表达载体及其应用
CN104099348B (zh) * 2013-04-15 2017-03-29 上海市农业科学院 一种来源于耐高温菌的重金属结合蛋白基因及其抗重金属应用
CN103555750B (zh) * 2013-05-17 2015-04-08 温州医科大学附属第二医院 一种人子宫肌瘤14-3-3 γ高表达载体的构建方法及应用
US20160116652A1 (en) * 2013-06-20 2016-04-28 Merck Patent Gmbh Method for controlling the optical properties of uv filter layers
KR101489844B1 (ko) * 2013-06-27 2015-02-06 강원대학교산학협력단 14-3-3 시그마 유전자 결손 마우스, 이를 이용한 인 비보 패혈증 연구모델 개발 방법 및 그 응용
WO2015031645A1 (en) 2013-08-28 2015-03-05 Washington University Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
AU2015330955A1 (en) 2014-10-08 2017-05-25 Central Adelaide Local Health Network Inc. Modulators of 14-3-3 functionality and uses thereof
KR101946884B1 (ko) * 2017-04-25 2019-02-13 고려대학교 산학협력단 대사체 분석을 이용한 베체트병의 진단방법
JP2019054181A (ja) * 2017-09-19 2019-04-04 東芝メモリ株式会社 半導体パッケージ
CN109596829A (zh) * 2017-12-07 2019-04-09 南京医科大学 一种肝癌标志蛋白及其检测方法
CA3086642A1 (en) 2017-12-21 2019-06-27 Resolys Bio, Inc. Compositions and methods of treatment of ehlers-danlos syndromes
CN114397442A (zh) * 2018-01-05 2022-04-26 科美诊断技术股份有限公司 检测14-3-3eta蛋白的均相免疫检测试剂盒及其应用
CN110579600B (zh) * 2018-05-23 2023-12-26 科美诊断技术股份有限公司 通过生物标记物联检体外评估类风湿性关节炎是否存在的方法
CN110579597A (zh) * 2018-05-23 2019-12-17 科美诊断技术股份有限公司 检测14-3-3 eta蛋白的非均相化学发光免疫检测试剂盒及其应用
CN110726843A (zh) * 2018-07-16 2020-01-24 科美诊断技术股份有限公司 检测14-3-3eta蛋白的化学发光免疫检测试剂盒及其应用
WO2020102623A1 (en) * 2018-11-15 2020-05-22 The University Of Toledo Materials and methods for the prevention of rheumatoid arthritis
WO2020138674A1 (ko) * 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물
MX2020014330A (es) * 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
CN109593131B (zh) * 2018-12-27 2021-09-03 南京医科大学 一种抗14-3-3η蛋白单克隆抗体及其用途
CN109897109B (zh) * 2019-01-30 2022-09-09 常州市第二人民医院 抗肿瘤标志蛋白单克隆抗体及其用途
US11248325B2 (en) 2019-11-19 2022-02-15 Whirlpool Corporation Laundry appliance having a processing belt
CN111606977B (zh) * 2020-05-27 2021-11-09 福建农林大学 一种利用GF14f蛋白靶向多肽配体调控水稻弱势籽粒灌浆的方法
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
KR20240086947A (ko) * 2022-12-09 2024-06-19 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
CN117024557B (zh) * 2023-10-10 2024-01-30 天津外泌体科技有限公司 14-3-3蛋白theta异构体作为细胞外囊泡支架蛋白的应用和细胞外囊泡
CN117899196B (zh) * 2024-03-18 2024-06-04 中国人民解放军总医院第一医学中心 14-3-3zeta蛋白或YWHAZ基因在角膜损伤治疗中的应用
WO2025202717A1 (en) * 2024-03-27 2025-10-02 Augurex Life Sciences Corp System and method for detection of 14-3-3 eta protein in capillary blood

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526714A (en) 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US6596476B1 (en) 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5948765A (en) 1996-03-15 1999-09-07 Washington University Inhibition of intracellular signal transduction by 14-3-3-binding peptides
US5998149A (en) 1996-04-05 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Method of detecting transmissible spongiform encephalopathies
US5814507A (en) * 1996-05-24 1998-09-29 Genentech, Inc. κ/μ-like protein tyrosine phosphatase, PTP λ
WO1998026293A1 (en) 1996-12-12 1998-06-18 Neuromark Methods of detecting transmissible spongiform encephalopathies by detecting 14-3-3 protein isoforms
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
DE19810721A1 (de) * 1998-03-12 1999-10-14 Werner Mueller Anwendung der 14-3-3 Proteine sowie Verfahren zur schnellen Bestimmung der 14-3-3 Proteine als sensitive Biomarker für Pollution u. a. mit polychlorierten Biphenylen (PCBs) und (Xeno)Östrogenen
CA2324284A1 (en) 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7105341B2 (en) 2000-03-06 2006-09-12 Rigel Pharmaceuticals. Inc. In vivo production of cyclic peptides
AU2001245838A1 (en) * 2000-03-17 2001-10-03 Gemini Science, Inc. Soluble mast cell function associated antigen (mafa) pharmaceutical compositionsand methods of making and using them
US20060062786A1 (en) 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR100380147B1 (ko) 2001-01-18 2003-04-11 주식회사 엘지생명과학 류마티스성 자가면역 항체의 검출방법 및 검출키트
US7335635B2 (en) * 2001-02-21 2008-02-26 Emory University 14-3-3 binding molecules as sensitizers for anticancer therapies
DE10131912A1 (de) 2001-06-06 2002-12-19 Werner E G Mueller Verwendung von 14-3-3 Proteinen und Verfahren zu deren Bestimmung
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
DE10159414A1 (de) 2001-12-04 2003-06-18 Infineon Technologies Ag Bipolar-Transistor und Verfahren zum Herstellen desselben
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2005049806A2 (en) * 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
US7101962B2 (en) * 2003-05-15 2006-09-05 Bristol-Myers Squibb Company Antibodies of the P2Y10 receptor useful in altering T lymphocyte function
US7199710B2 (en) 2003-06-03 2007-04-03 Kabushiki Kaisha Tokai Rika Denki Controller for remote control system
CA2533618A1 (en) 2003-06-25 2004-12-29 Queen's University At Kingston Methods for diagnosing, monitoring, staging and treating heart failure
EP1701772A4 (en) * 2003-11-21 2012-03-28 Univ Johns Hopkins BIOMOLECOLE PARTITIONING MOTIVES AND USES THEREOF
TWI281473B (en) 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
EP1745149A4 (en) 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
US20070253961A1 (en) 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
CA2600844A1 (en) 2005-03-14 2006-09-21 Medimmune, Inc. Macromolecules comprising a thioether cross-link
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
PL2021792T3 (pl) 2006-05-09 2013-08-30 Univ British Columbia Rozpuszczone białkowe markery zapalenia stawów
AU2008307634A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009046267A1 (en) 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
US7919262B2 (en) 2007-11-07 2011-04-05 The Uab Research Foundation 14-3-3 proteins for diagnosis of Parkinson's disease
BRPI0819063A2 (pt) 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
EP2277049A4 (en) 2008-05-09 2012-05-30 Univ Duke AUTOANTIKÖRPER FOR THE PROOF AND THE TREATMENT OF CANCER
JP5905003B2 (ja) 2010-07-09 2016-04-20 ソマロジック・インコーポレーテッド 肺癌バイオマーカーとその使用
ES2688048T3 (es) 2010-09-27 2018-10-30 Somalogic, Inc. Biomarcadores del mesotelioma y usos de los mismos
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
BRPI0819063A2 (pt) 2020-08-18
US20110052573A1 (en) 2011-03-03
KR20100100912A (ko) 2010-09-15
AU2008329529A1 (en) 2009-06-04
US9079947B2 (en) 2015-07-14
KR20160127177A (ko) 2016-11-02
US20200157195A1 (en) 2020-05-21
KR20100099221A (ko) 2010-09-10
US20220106386A1 (en) 2022-04-07
US12275779B2 (en) 2025-04-15
EP2222704A1 (en) 2010-09-01
JP2011504876A (ja) 2011-02-17
CA2706479A1 (en) 2009-06-04
CN101952313B (zh) 2017-12-15
US20160185842A1 (en) 2016-06-30
IL205948A (en) 2017-09-28
CN101925364A (zh) 2010-12-22
IL205948A0 (en) 2010-11-30
JP2015096511A (ja) 2015-05-21
CN101925364B (zh) 2014-04-30
BRPI0819066A2 (pt) 2020-08-18
WO2009067811A1 (en) 2009-06-04
JP6054936B2 (ja) 2016-12-27
EP3192807B1 (en) 2026-04-29
JP2011504877A (ja) 2011-02-17
WO2009067820A1 (en) 2009-06-04
CA2706479C (en) 2023-02-28
JP2014221758A (ja) 2014-11-27
EP3192807A1 (en) 2017-07-19
US20160039918A1 (en) 2016-02-11
KR20170116184A (ko) 2017-10-18
EP2222704A4 (en) 2011-02-09
HK1151728A1 (en) 2012-02-10
HK1253516A1 (zh) 2019-06-21
JP5781764B2 (ja) 2015-09-24
CA2706476A1 (en) 2009-06-04
US20110027269A1 (en) 2011-02-03
EP2224955A4 (en) 2011-02-16
JP5615181B2 (ja) 2014-10-29
AU2008329529B2 (en) 2015-02-19
JP2017149716A (ja) 2017-08-31
PL3192807T3 (pl) 2026-07-27
EP2224955A1 (en) 2010-09-08
AU2008329466B2 (en) 2015-04-09
CN101952313A (zh) 2011-01-19
IL254157B (en) 2019-05-30
EP3192808A1 (en) 2017-07-19
JP6105516B2 (ja) 2017-03-29
IL205907A0 (en) 2010-11-30
US10995136B2 (en) 2021-05-04
CN107880122A (zh) 2018-04-06
CA2706476C (en) 2021-08-03
IL254157A0 (en) 2017-10-31
KR101945394B1 (ko) 2019-02-07
AU2008329466A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
US12275779B2 (en) 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
AU2015202689B2 (en) 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
HK1240954A1 (en) 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
HK1152316B (en) 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
HK1152316A (en) 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
HK1240955A1 (en) 14-3-3 antagonists for the prevention and treatment of arthritis
HK1151728B (en) 14-3-3 antagonists for the prevention and treatment of arthritis

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180905

Application number text: 1020167029986

Filing date: 20161026

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181005

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190102

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190603

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190102

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I